Dr Prem Global Healthcare Logo

'Don't prescribe Exubera' recommended by NICE

National Institute for Health and Clinical Excellence(NICE) has recommended not to prescribe Exubera on the state health service. Pfizer called it as perverse action.

According to Pfizer, Exubera ruling will deprive patients. It is the first alternative to insulin injections since the 1920s. It is approved for a treatment of diabetes patients in Europe and US. According to NICE it did not offer sufficient benefits in camparing with conventional insulin injections. The cost of using Exubera is 1102 pounds per patient a year.

Some other groups are are on the way to develop another inhaled insulin products, including Eli Lilly & Co and Alkermes Inc.

Read

Recent Articles:

Scroll to Top